Skip to main content
Clinical Trials/NCT06253000
NCT06253000
Recruiting
Not Applicable

Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation

Bakulev Scientific Center of Cardiovascular Surgery1 site in 1 country158 target enrollmentJune 10, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
Bakulev Scientific Center of Cardiovascular Surgery
Enrollment
158
Locations
1
Primary Endpoint
Cerebral events
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.

The main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and/or cryoenergy to eliminate destructive damage to the left atrium (LA).

The aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.

Registry
clinicaltrials.gov
Start Date
June 10, 2023
End Date
December 30, 2026
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Bakulev Scientific Center of Cardiovascular Surgery
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age over 18 years old;
  • Atrial fibrillation resistant to antiarrhythmic therapy;
  • Persistent and long-persisting form of atrial fibrillation;
  • The patient's consent to participate in the study.

Exclusion Criteria

  • Age under 18 and over 80 years old;
  • The presence of another cardiac pathology requiring surgical treatment;
  • Congenital heart defects;
  • Previous "open" cardiac surgery;
  • Bone marrow diseases;
  • Pathology of the blood coagulation system;
  • The left ventricular ejection fraction is less than 40%;
  • Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min);
  • Drug-resistant hypertension (despite hypotensive therapy);
  • Organically altered mitral valve;

Outcomes

Primary Outcomes

Cerebral events

Time Frame: From the date of ablation until the date of the event, assessed up to 24 months.

The number of patients who had a stroke or acute cerebrovascular accident or a transient ischemic attack within 24 months after ablation.

Secondary Outcomes

  • Recurrence of AF(From the date of ablation until the date of recurrent atrial fibrillation, assessed up to 24 months.)
  • Hospital mortality(From the date of ablation until the date of death, assessed up to 5 days.)
  • Long-term mortality(From the date of ablation until the date of death, assessed up to 24 months.)
  • Non-lethal events(From the date of ablation to the date of any of the listed events, assessed up to 5 days.)

Study Sites (1)

Loading locations...

Similar Trials